A dose modified ifosfamide, epirubicin, and etoposide (
IVE
) regimen was prospectively assessed for its efficacy in mobilizing peripheral blood stem cells for autologous transplantation. Two patients with Hodgkin’s lymphoma and two with non-Hodgkin’s lymphoma who were undergoing stem cell therapy were studied. All patients had a history of multiple treatments with insufficient stem cell mobilization. The dose modified
IVE
regimen consisted of ifosfamide 3 g/m
2 intravenously (IV) administered on days 1-2 in combination with epirubicin 50 mg/m
2 IV on day 1 and etoposide 200 mg/m
2 (100 mg/m
2 in two patients with complete remission) IV on days 1-3. The ifosfamide dosage was reduced to two-thirds of the original protocol. A substantial high yield of CD34
+ cells was achieved when patients were treated with a dose-modified
IVE
regimen, compared with that during the previous regimen (two with the ifosfamide, carboplatin, and etoposide [ICE] regimen, one with high-dose cyclophosphamide and one with the original
IVE
regimen). Two patients who had refractory and residual disease received a 200 mg/m
2 dose of etoposide, which resulted in tumor reduction (one patient with complete remission and one with further reduction in tumor size). After the
IVE
regimen, all four patients had a sufficient yield of CD34
+ cells in total, which was available for stem cell transplantation. Hematological and non-hematological toxicities were comparable in all regimens. This single-center prospective study demonstrated that the dose-modified
IVE
regimen can be used as a safe treatment with high mobilizing efficacy in heavily pretreated lymphoma patients.
抄録全体を表示